Save this page for future reference
You may not see this ad again, but you can return here whenever you have a potentially eligible patient.
Bookmark this page in your browser:
Now Enrolling:
The RETAIN Study
Patients in your area with periprosthetic joint infection (PJI) of the knee may be able to participate
Check Patient Eligibility
About the RETAIN study
RETAIN is a randomized, placebo-controlled study for adults with PJI following total knee arthroplasty (TKA).
PJI impacts thousands of patients each year.1 While the Debridement, Antibiotics, and Implant Retention (DAIR) procedure is often the primary treatment strategy, DAIR is associated with high failure rates of up to 60% at 4 years.2 A major cause of failure is the presence of bacterial biofilm, which is exceptionally difficult to eradicate with oral or intravenous (IV) antibiotics.
RETAIN is developing PLG0206 (zaloganan), an investigational antimicrobial peptide with activity against biofilm for the treatment of PJI in patients
undergoing DAIR.
PLG0206 (zaloganan) is:
An engineered cationic antibiotic peptide based on naturally occurring antimicrobial peptides (AMPs)
Designed to be used as an irrigation solution during DAIR to achieve high bactericidal concentrations at the site of infection and eliminate biofilm with limited systemic exposure
RETAIN is now enrolling. Your patients with PJI could qualify.
Check Patient Eligibility
Reference
1. Patel R. Periprosthetic joint infection. N Engl J Med. 2023;388(3):251-262.
2. Urish KL, Bullock AG, Kreger AM, et al. Infected Implant Consortium. A multicenter study of irrigation and debridement in total knee arthroplasty periprosthetic joint infection: treatment failure is
high. J Arthroplasty. 2018;33(4):1154-1159.
Who can participate in this study?
Your patient(s) may qualify if they:
Are 18 to less than 86 years of age
Have PJI following TKA
Must not have suspected fungal PJI
Are DAIR-eligible with a well-fixed prosthesis — surgeon is planning DAIR with exchange of modular components
Have no history of prior PJI in the index joint
Have no more than 1 prior revision of the index joint
Are not expected to require long-term (> 6 months) antibiotic therapy
Check Patient Eligibility
Save this page for future reference
You may not see this ad again, but you can return here whenever you have a potentially eligible patient.
Bookmark this page in your browser:
